Compare RPGL & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RPGL | HCWB |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | Singapore | United States |
| Employees | 8 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 2.9M |
| IPO Year | N/A | 2021 |
| Metric | RPGL | HCWB |
|---|---|---|
| Price | $0.44 | $0.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | ★ 1.3M | 619.4K |
| Earning Date | 05-16-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,099,750.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.40 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $0.25 |
| 52 Week High | $8.44 | $17.80 |
| Indicator | RPGL | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 42.79 | 45.40 |
| Support Level | $0.39 | $0.25 |
| Resistance Level | $0.64 | $0.78 |
| Average True Range (ATR) | 0.10 | 0.04 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 27.68 | 81.30 |
Republic Power Group Ltd is a provider of customized ERP software solutions, consulting and technical support services, and peripheral hardware to corporate clients and government agencies, including airports, cruise terminals, and technology, trading, and logistics companies. The Company operates from Singapore and has historically served clients in Singapore and Malaysia, offering ERP systems with functions such as accounting, procurement, workflow automation, real-time monitoring, and capabilities including planning, surveillance, and threat detection. The Company leverages artificial intelligence and modular algorithms to address complex operational requirements and integrates sensors, controls, and other hardware to enable IoT connectivity with autonomous or semiautonomous outcomes.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.